Welcome to our dedicated page for Mediwound news (Ticker: MDWD), a resource for investors and traders seeking the latest updates and insights on Mediwound stock.
MediWound Ltd (Nasdaq: MDWD) is a biopharmaceutical innovator developing enzymatic therapeutics for non-surgical wound care. This page provides investors and healthcare professionals with essential updates on clinical advancements, regulatory milestones, and strategic developments.
Access consolidated information about NexoBrid adoption, EscharEx clinical trials, and pipeline progress. Stay informed about financial results, partnership announcements, and market expansion initiatives directly impacting MediWound's position in wound care innovation.
Key updates include FDA/EMA regulatory decisions, burn treatment protocols, chronic wound therapy breakthroughs, and peer-reviewed research findings. All content is verified through primary sources to ensure accuracy for investment and clinical decision-making.
Bookmark this page for streamlined access to MediWound's latest developments. Combine our updates with SEC filings and earnings call transcripts for comprehensive analysis of this enzymatic therapeutics leader.
MediWound Ltd. (Nasdaq: MDWD) has expanded its global presence by entering the UAE market through a distribution agreement with Ghassan Aboud Group (GAG). GAG will exclusively market NexoBrid for severe burn treatment, pending regulatory approval expected within a year. This partnership is influenced by the recent Abraham Accords. NexoBrid is a biological product that safely removes nonviable burn tissue and is already approved in Europe and other regions. The FDA is reviewing its Biologics License Application, with a target decision date of June 29, 2021.
MediWound Ltd. (Nasdaq: MDWD) reported third-quarter 2020 revenues of $6.6 million, a 29% increase year-over-year, primarily due to NexoBrid® procurement by BARDA. Gross profit rose to $2.8 million, achieving a 42% gross margin. The FDA accepted the BLA for NexoBrid with a PDUFA goal date set for June 29, 2021. However, net losses for the nine-month period were $7.5 million, up from a profit of $8.4 million in 2019, impacted by the absence of a significant upfront license payment. MediWound's cash reserves stood at $25 million as of September 30, 2020, reflecting efficient operational management.
MediWound Ltd. (Nasdaq: MDWD) announced the upcoming release of its third-quarter financial results for the period ending September 30, 2020, scheduled for November 10, 2020, at 7:00 am ET. Following the announcement, a conference call will be held at 8:30 am ET to discuss the results. MediWound specializes in innovative therapies for severe burn and wound management, with notable products like NexoBrid and EscharEx, both leveraging patented proteolytic enzyme technology. NexoBrid has received marketing authorization in several countries, underscoring the company's regulatory progress.
MediWound Ltd. has completed enrollment for its Phase 3 pediatric clinical study of NexoBrid, aimed at treating severe burns in children. Following FDA's approval for expanded access to pediatric patients, the study involves 145 participants and will compare NexoBrid against standard care over a 12 and 24-month follow-up. Top-line results are expected in the second half of 2021. Funded by BARDA, the trial addresses significant challenges faced in pediatric burn management, potentially expanding NexoBrid's applications.
MediWound Ltd. (Nasdaq: MDWD) is investigating the effects of EscharEx on biofilm burden in chronic wounds, focusing on its potential to improve wound healing. Biofilms are linked to delayed healing and infections in 60%-100% of chronic wounds. Conventional treatment can be painful and costly, leading to interest in enzymatic debridement as a less invasive alternative. Preclinical studies suggest enzymes, including bromelain, could effectively disrupt biofilms. MediWound intends to conduct pharmacological studies to evaluate EscharEx's potential benefits on biofilms in chronic wounds.
MediWound Ltd. (NASDAQ: MDWD) announced that the FDA accepted its Biologics License Application (BLA) for NexoBrid® for eschar removal in patients with deep partial and full-thickness thermal burns. The FDA has set a PDUFA date of June 29, 2021, with no advisory committee meeting planned. The submission includes data from the pivotal Phase 3 DETECT trial that met its primary and secondary endpoints. NexoBrid is already approved in the EU and designated as an orphan biologic drug in multiple regions. Vericel Corporation holds exclusive North American rights, and BARDA supports the development.
MediWound Ltd. (Nasdaq: MDWD), a biopharmaceutical company specializing in wound management, announced investor presentations in September 2020. CEO Sharon Malka will present at three virtual conferences: the Wells Fargo Virtual Healthcare Conference on September 10, H.C. Wainwright Annual Global Investment Conference on September 14, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21. MediWound is known for its innovative products, including NexoBrid and EscharEx, targeting severe burns and hard-to-heal wounds.
MediWound Ltd. (NASDAQ: MDWD) and its partner Vericel Corporation (NASDAQ: VCEL) announced that BARDA has accepted a $16.5 million shipment of NexoBrid, intended for public health emergency preparedness. This procurement includes additional deliveries through 2021, with an option for up to $50 million. The collaboration aims to ensure supply and training for treating severe burn injuries amid COVID-19. MediWound also submitted a Biologics License Application to the FDA for NexoBrid, which has been effective in clinical studies as a non-surgical solution for burn tissue removal.
MediWound Ltd. (NASDAQ: MDWD) announced the submission of a Biologics License Application (BLA) to the FDA for its product NexoBrid, designed for eschar removal in adults with deep partial-thickness and full-thickness thermal burns. The submission includes data from the successful Phase 3 DETECT study, which demonstrated safety and efficacy. NexoBrid is already approved in the EU and other regions and is supported by BARDA with a commitment of $16.5 million for procurement. This milestone could significantly benefit severe burn victims and public health preparedness in the U.S.
MediWound Ltd. (Nasdaq: MDWD) reported its Q1 2020 financial results with total revenues of $4.4 million, a significant increase from $0.5 million in Q1 2019. The operating loss narrowed to $2.2 million from $3.6 million year-over-year. Operating cash flow was $2.1 million, and the company held $27.3 million in cash and short-term investments, carrying no debt. MediWound resumed clinical trials for EscharEx treatment and expanded its contract with BARDA for NexoBrid, reflecting ongoing operational stability amidst the COVID-19 pandemic.
